MGF and Cardiac Biology Research: Mechano Growth Factor, Cardiomyocyte Survival and Heart Repair Mechanisms UK 2026

Research Use Only. MGF (Mechano Growth Factor) and PEG-MGF are not licensed cardiac therapeutics in the UK. All content describes preclinical and investigational research biology. Not medical advice.

Mechano Growth Factor (MGF, also known as IGF-1Ec) is a splice variant of the IGF-1 gene produced by alternative splicing of exon 5, yielding a unique 24-amino acid C-terminal E-peptide extension (Ec domain) that distinguishes it from liver-derived systemic IGF-1 (IGF-1Ea). While MGF is most studied in skeletal muscle following mechanical loading, a growing body of research documents direct cardioprotective and regenerative properties in the heart — a tissue under continuous mechanical and metabolic demand. This post examines the MGF receptor biology, cardiomyocyte signalling, and preclinical cardiac models relevant to MGF research.

MGF and Its Distinct Receptor Biology in Heart

MGF differs from mature IGF-1 in both structure and receptor engagement kinetics. The intact precursor MGF (with Ec peptide) does not efficiently bind IGF-1R until proteolytically processed to release mature IGF-1 domain — but the Ec peptide itself engages a distinct receptor on muscle and cardiac cells that remains pharmacologically uncharacterised (the “MGF receptor” hypothesis). Evidence for Ec peptide-specific signalling comes from studies showing that the synthetic Ec peptide alone (the 24-amino acid C-terminal fragment, commercially available as “MGF C-terminal peptide”) produces cardiomyocyte effects independent of IGF-1R blockade (not abolished by IGF-1R antibody αIR3 or picropodophyllin/PPP).

Conversely, mature IGF-1 domain released by protease processing engages IGF-1R → IRS-1 → PI3K-Akt Ser-473 → multiple downstream pro-survival effectors. PEG-MGF (polyethylene glycol-conjugated MGF C-terminal peptide) provides extended t½ (~24–72h vs ~2h for unmodified peptide) enabling sustained Ec-domain signalling in preclinical cardiac models without continuous infusion.

Cardiomyocyte Survival Signalling

PI3K-Akt-mTOR pathway: MGF Ec-peptide at 25–200 ng/ml activates Akt Ser-473 phosphorylation in neonatal rat ventricular cardiomyocytes (NRVCMs) and adult rat ventricular cardiomyocytes (ARVCMs) within 15–60 minutes (western blot time-course). Downstream Akt targets: GSK-3β Ser-9 phosphorylation (inhibiting apoptotic priming and promoting glycogen synthesis); FOXO3a Thr-32 phosphorylation (nuclear exclusion → reduced pro-apoptotic Bim/FasL transcription); and mTORC1-S6K1-4E-BP1 (cap-dependent translation of hypertrophic/survival proteins).

ERK1/2 MAPK pathway: MGF activates ERK1/2 Thr-202/Tyr-204 in cardiomyocytes, promoting cell cycle re-entry markers (Ki-67, phospho-histone H3) in a small fraction of adult cardiomyocytes — relevant to the concept of adult cardiomyocyte proliferation that has received renewed research interest. ERK1/2 additionally activates the cardiac transcription factor GATA4 (Ser-105 phosphorylation) driving expression of BNP/BNIP3L and anti-apoptotic Bcl-xL/Bcl-2.

Anti-apoptotic mechanisms: Simulated ischaemia (90-min hypoxia/low glucose + 60-min reoxygenation, H/R model in ARVCMs) produces significant NRVCM/ARVCM apoptosis (TUNEL, Annexin V-PI flow, LDH release, caspase-3 cleavage). MGF Ec-peptide pre-treatment (25–100 ng/ml, 30 min pre-H/R) dose-dependently reduces: TUNEL+ index; cleaved caspase-3 (Asp-175 western); cytochrome c cytosolic release (mitochondrial fractionation western); and mitochondrial membrane potential loss (JC-1 aggregate:monomer ratio). Bcl-2/Bax ratio in cardiomyocyte lysate (western) shifts anti-apoptotically.

Myocardial Infarction: In Vivo Models

Coronary artery ligation (permanent MI): Permanent ligation of the left anterior descending (LAD) coronary artery in rats or mice produces a defined infarction zone (apex, anterior wall, interventricular septum) with cardiomyocyte necrosis peaking at 24–48h and scar formation over 2–4 weeks. MGF or PEG-MGF administered via: intramyocardial injection at ligation (5–50 µg in 25 µl PBS, 2–3 injection sites at infarct border zone); or subcutaneous PEG-MGF (0.5–2 mg/kg, starting 24h post-MI for 2 weeks).

Endpoint battery at 4 weeks: echocardiography under 1.5% isoflurane (ejection fraction % LVEF, fractional shortening %FS, LV end-diastolic/systolic volume and diameter, E/A ratio for diastolic function); invasive pressure-volume (PV) loop (1.4F Millar catheter via carotid artery retrograde into LV, end-systolic pressure-volume relationship ESPVR slope = Emax, dP/dt max and min, relaxation τ Weiss constant); infarct size (TTC 2,3,5-triphenyltetrazolium chloride at 24h post-MI OR Masson trichrome % fibrosis area at 4 weeks); cardiomyocyte apoptosis in border zone (TUNEL + troponin I co-staining, TUNEL+ TnI+ per HPF); angiogenesis (CD31+ vessel density in border zone, IHC morphometry); and fibrosis (hydroxyproline content µg/mg LV, Masson trichrome % area).

Ischaemia-reperfusion injury (IRI): Temporary LAD ligation (30–45 min ischaemia) followed by reperfusion (24h–4 weeks) produces IRI distinct from permanent MI: the reperfusion injury component (lethal reperfusion, caused by mitochondrial permeability transition pore opening within minutes of reflow) kills additional viable cardiomyocytes beyond those lost during ischaemia. MGF administered immediately at reperfusion onset (peri-reperfusion window, clinically relevant as it models catheterisation lab timing) reduces lethal reperfusion injury via: Akt-GSK-3β Ser-9 phosphorylation preventing mPTP opening (measured by calcein-AM/CoCl₂ quenching assay or atractyloside-induced swelling in isolated mitochondria); reduced troponin I/T serum release at 6/24h; and preserved LVEF at 4 weeks echocardiography.

Cardiac Progenitor and Regenerative Biology

The adult mammalian heart has limited but non-zero regenerative capacity: cardiomyocyte turnover of approximately 0.5–1%/year has been documented by carbon-14 retrospective birth dating and BrdU incorporation studies. MGF research has examined whether Ec-peptide signalling can expand this limited regenerative response by promoting: cardiac progenitor cell (CPC, defined as c-Kit+/Lin- or Sca-1+/CD31- in mouse heart) proliferation and differentiation; cardiosphere-derived cell (CDC) expansion ex vivo and engraftment; and endogenous cardiomyocyte cell cycle re-entry.

MGF Ec-peptide promotes c-Kit+ CPC proliferation (Ki-67 immunofluorescence, BrdU incorporation over 24h) and reduces CPC apoptosis in simulated ischaemia. In vivo, intramyocardial injection of MGF increases c-Kit+ cell density in border zone at day 7 post-MI (IHC, per mm² quantification). Whether these c-Kit+ cells represent true cardiac progenitors or other c-Kit-expressing populations (mast cells, endothelial progenitors) requires lineage tracing validation (Rosa26-lacZ reporter crossed with c-Kit-Cre in mice) — a critical methodological control in contemporary cardiac progenitor research given controversy in the field.

Cardiac Hypertrophy Research

Physiological cardiac hypertrophy (exercise-adapted, concentric with preserved or improved systolic function) is mediated by IGF-1R-PI3K-Akt-mTORC1 signalling and is mechanistically distinct from pathological hypertrophy (pressure overload-induced, eccentric with fibrosis and eventual failure, driven by MAPK-NFAT-Gq-calcineurin). MGF in cardiomyocyte culture promotes physiological hypertrophy endpoints: increased cell area (calcein AM/phase-contrast morphometry, µm² per cell), sarcomere organisation (sarcomeric α-actinin immunofluorescence, Z-disc regularity), and protein synthesis rate (puromycin incorporation SUnSET assay) without NFAT nuclear translocation or BNP/β-MHC fetal gene re-expression — hallmarks of pathological hypertrophy. TAC (transverse aortic constriction, 26-gauge needle banding) produces pressure overload pathological hypertrophy; MGF treatment in TAC tests whether IGF-1-like pro-physiological signalling reduces TAC-induced HW/BW ratio, fibrosis, and transition from compensated hypertrophy to failure.

Summary

MGF (IGF-1Ec splice variant) engages dual receptor biology in the heart — IGF-1 domain via IGF-1R-PI3K-Akt-ERK and Ec-domain via a putative distinct receptor — producing cardiomyocyte survival, anti-apoptotic, and limited regenerative signalling. In permanent LAD ligation and IRI models, MGF reduces infarct size, preserves LVEF, reduces border zone cardiomyocyte apoptosis, and promotes CD31+ angiogenesis. PEG-MGF extends pharmacokinetic half-life enabling less frequent dosing. In physiological hypertrophy contexts, IGF-1R-Akt-mTOR-driven sarcomere organisation and protein synthesis without fetal gene re-expression distinguishes MGF from pathological Gq-calcineurin-NFAT signalling. Cardiac progenitor biology requires lineage tracing validation to confirm c-Kit+ identity. Research designs must include IGF-1R specificity controls (αIR3 or PPP) to delineate Ec-peptide-specific from mature IGF-1-domain effects.